ArticleTranslational oncology2026
Integrated bioinformatics and experimental validation identifies CLIC6 as a novel tumor suppressor regulating NF-κB signaling and immune microenvironment in nasopharyngeal carcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNasopharyngeal carcinoma (NPC) is an Epstein-Barr virus-associated malignancy. Tumor-associated macrophages play a pivotal role in NPC development, but molecular mechanisms remain unclear. This study aimed to identify M1 macrophage-associated hub genes and investigate their biological functions in NPC via bioinformatics and experimental validation.
methodsGSE12452 and GSE53819 datasets were integrated to assess immune cell infiltration using CIBERSORT. WGCNA identified gene modules correlated with M1 macrophages. Hub genes were identified by intersecting differentially expressed genes with module genes, followed by LASSO regression and clinical specimen validation. CCK-8, Transwell assays, and macrophage co-culture systems were used to evaluate CLIC6 effects on NPC cell proliferation, invasion, and M1 polarization. RNA-seq and Western blot were performed to explore downstream mechanisms, with rescue experiments using NF-κB activator or inhibitor.
resultsM1 macrophages were significantly enriched in NPC tissues and negatively correlated with cilia-related gene modules. Six hub genes (MUC16, MS4A8, MUC20, AMIGO1, PHYHD1, CLIC6) were identified, with CLIC6 showing significant downregulation in NPC tissues and cell lines and negative correlation with M1 macrophages. CLIC6 recombinant protein promoted NPC cell proliferation and invasion while inhibiting M1 polarization, whereas CLIC6 silencing produced opposite effects. Mechanistically, CLIC6 suppressed NF-κB signaling by inhibiting IκBα and p65 phosphorylation, confirmed by RNA-seq and Western blot. Functional rescue experiments demonstrated that NF-κB modulation reversed CLIC6-mediated effects.
conclusionCLIC6 functions as a tumor suppressor in NPC by inhibiting NF-κB signaling, thereby regulating tumor cell proliferation, invasion, and macrophage polarization. The CLIC6-NF-κB axis represents a potential diagnostic biomarker and therapeutic target for NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.